Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Watkins

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Cancer Medicine|April 11, 2019
Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)Muhammad Furqan, Travis P Snyders, Mohammed U Saqlain, et al.
Prostate International|October 1, 2016
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survivalJoshua B Kaelberer, Michael A O'Donnell, Darrion L Mitchell, et al.
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Head & Neck|January 22, 2009
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancersJohn M Watkins, Keisuke S Shirai, Amy E Wahlquist, et al.
International Journal of Radiation Oncology, Biology, Physics|October 19, 2010
Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement GroupsA Jason Zauls, John M Watkins, Amy E Wahlquist, et al.
Clinical Genitourinary Cancer|September 6, 2015
Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future DirectionsDarrion L Mitchell, Chad R Tracy, John M Buatti, et al.
American Journal of Surgery|October 20, 2009
Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapyJennifer L Harper, John M Watkins, A Jason Zauls, et al.
Japanese Journal of Clinical Oncology|November 19, 2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancerJohn M Watkins, Andris Jason Zauls, Patricia L Kearney, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer Medicine|April 11, 2019
Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)Muhammad Furqan, Travis P Snyders, Mohammed U Saqlain, et al.
Prostate International|October 1, 2016
Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survivalJoshua B Kaelberer, Michael A O'Donnell, Darrion L Mitchell, et al.
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Head & Neck|January 22, 2009
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancersJohn M Watkins, Keisuke S Shirai, Amy E Wahlquist, et al.
International Journal of Radiation Oncology, Biology, Physics|October 19, 2010
Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement GroupsA Jason Zauls, John M Watkins, Amy E Wahlquist, et al.
Clinical Genitourinary Cancer|September 6, 2015
Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and Future DirectionsDarrion L Mitchell, Chad R Tracy, John M Buatti, et al.
American Journal of Surgery|October 20, 2009
Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapyJennifer L Harper, John M Watkins, A Jason Zauls, et al.
Japanese Journal of Clinical Oncology|November 19, 2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancerJohn M Watkins, Andris Jason Zauls, Patricia L Kearney, et al.
Pageof 4